Edaravone dextrocamphorol combined with intravenous thrombolysis enhances recovery in acute ischemic stroke

To evaluate the effect of edaravone dextrocamphorol on neurotrophic status and functional recovery in patients undergoing intravenous thrombolysis for acute ischemic stroke.

This single-center retrospective study enrolled 100 patients with acute ischemic stroke. Patients were divided into two groups: the observation group (n = 45), who received both intravenous alteplase and edaravone dextrocamphorol treatment, and the control group (n = 55), who received intravenous thrombolysis with alteplase alone. Clinical indicators that were compared between groups included baseline characteristics, NIHSS scores, nutritional status (albumin, hemoglobin, prealbumin, and transferrin), diet satisfaction, and quality of life (SF-36), and negative psychological symptoms.

Compared to the control group, the observation group demonstrated significantly higher diet satisfaction, improved dietary-related symptoms, and better neurological function recovery (all P < 0.05). SF-36 scores, including psychological, material, and total functional domains, were also superior in the observation group (P < 0.05 for all). Additionally, nutritional status and negative psychological symptoms (P < 0.05) improved significantly in the observation group.

Edaravone dextrocamphorol, when added to intravenous thrombolysis, significantly enhances recovery in acute ischemic stroke. This strategy improves diet satisfaction, neurological function, quality of life, nutritional status, and psychological well-being.